Friday, September 25th | 7 Tishri 5781

Subscribe
June 3, 2019 9:45 am

Israeli Study May Provide Hope for Some Pancreatic Cancer Patients

avatar by JNS.org

A researcher at the Technion-Israel Institute of Technology in Haifa on Feb. 19, 2019. Photo: Hadas Parush/Flash90.

JNS.org – A groundbreaking study at Israel’s Sheba Medical Center at Tel Hashomer has determined that a targeted cancer therapy drug developed in partnership with pharmaceutical companies AstraZeneca and Merck & Co. Inc. delays the progression of a specific strain of pancreatic cancer, offering “potential hope” for patients suffering from the 12th most common cancer worldwide.

Talia Golan, head researcher at the Sheba Medical Center Pancreatic Cancer Center, has been testing the safety and efficacy of a new treatment regimen based on olaprib tablets, a medication that attacks a certain enzyme important for the cell development of several forms of cancer.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.